ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced that management will provide an update on its meeting with the U.S. Food and Drug Administration (FDA) on the regulatory path for Zenvia™ for the treatment of involuntary emotional expression disorder during a conference call to be held Wednesday, February 28, 2007 at 8:00 a.m. Eastern time / 5:00 a.m. Pacific time. The call will be webcast live through AVANIR’s corporate website at www.avanir.com and will feature AVANIR’s President and Chief Executive Officer Eric Brandt and Vice President of Clinical and Medical Affairs Randall Kaye, M.D. A press release summarizing the highlights of the Company’s FDA meeting is expected to be released on February 28 prior to the conference call.
